WB 1:500-1:2000; IHC 1:100-1:300; ELISA 1:5000; IF 1:50-200
Formulation
Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide.
Specificity
This antibody detects endogenous levels of FoxO1/3 only when phosphorylated at Human:S322 or S325, Mouse:S319 or S322, Rat:S316 or S319..The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):SNAsTIsG
Purification
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen.
Storage
-15°C to -25°C/1 year(Do not lower than -25°C)
Concentration
1 mg/ml
MW(Observed)
97kD
Modification
Phospho
Clonality
Polyclonal
Isotype
IgG
Related Products
Secondary Antibodies
Goat Anti Mouse IgG(H+L) (HRP)
RS0001
More→
Secondary Antibodies
Goat Anti Rabbit IgG(H+L) (HRP)
RS0002
More→
Primary Antibodies
β-actin (PTR2364) Mouse mAb
YM3028
More→
Primary Antibodies
GAPDH (PTR2304) Mouse mAb
YM3029
More→
Antigen&Target Information
Immunogen:
The antiserum was produced against synthesized peptide derived from human FOXO1A/3A around the phosphorylation site of Ser322 and Ser325. AA range:291-340
show all
Specificity:
This antibody detects endogenous levels of FoxO1/3 only when phosphorylated at Human:S322 or S325, Mouse:S319 or S322, Rat:S316 or S319..The name of modified sites may be influenced by many factors, such as species (the modified site was not originally found in human samples) and the change of protein sequence (the previous protein sequence is incomplete, and the protein sequence may be prolonged with the development of protein sequencing technology). When naming, we will use the "numbers" in historical reference to keep the sites consistent with the reports. The antibody binds to the following modification sequence (lowercase letters are modification sites):SNAsTIsG
show all
Gene Name:
FOXO1/FOXO3
show all
Protein Name:
Forkhead box protein O1/3
show all
Other Name:
FOXO1 ;
FKHR ;
FOXO1A ;
Forkhead box protein O1 ;
Forkhead box protein O1A ;
Forkhead in rhabdomyosarcoma ;
FOXO3 ;
FKHRL1 ;
FOXO3A ;
Forkhead box protein O3 ;
AF6q21 protein ;
Forkhead in rhabdomyosarcoma-like 1
This gene belongs to the forkhead family of transcription factors which are characterized by a distinct forkhead domain. The specific function of this gene has not yet been determined; however, it may play a role in myogenic growth and differentiation. Translocation of this gene with PAX3 has been associated with alveolar rhabdomyosarcoma. [provided by RefSeq, Jul 2008],
show all
Function:
Disease:Chromosomal aberrations involving FOXO1 are a cause of rhabdomyosarcoma 2 (RMS2) [MIM:268220]; also known as alveolar rhabdomyosarcoma. Translocation (2;13)(q35;q14) with PAX3; translocation t(1;13)(p36;q14) with PAX7. The resulting protein is a transcriptional activator.,Function:Transcription factor.,PTM:Phosphorylated by AKT1; insulin-induced (By similarity). IGF1 rapidly induces phosphorylation of Ser-256, Thr-24, and Ser-319. Phosphorylation of Ser-256 decreases DNA-binding activity and promotes the phosphorylation of Thr-24, and Ser-319, permitting phosphorylation of Ser-322 and Ser-325, probably by CK1, leading to nuclear exclusion and loss of function. Phosphorylation of Ser-329 is independent of IGF1 and leads to reduced function. Phosphorylated upon DNA damage, probably by ATM or ATR.,similarity:Contains 1 fork-head DNA-binding domain.,subcellular location:Shuttles between cytoplasm and nucleus.,subunit:Interacts with LRPPRC.,tissue specificity:Ubiquitous.,
show all
Cellular Localization:
Cytoplasm . Nucleus . Shuttles between the cytoplasm and nucleus. Largely nuclear in unstimulated cells (PubMed:11311120, PubMed:12228231, PubMed:19221179, PubMed:21245099, PubMed:20543840, PubMed:25009184). In osteoblasts, colocalizes with ATF4 and RUNX2 in the nucleus (By similarity). Serum deprivation increases localization to the nucleus, leading to activate expression of SOX9 and subsequent chondrogenesis (By similarity). Insulin-induced phosphorylation at Ser-256 by PKB/AKT1 leads, via stimulation of Thr-24 phosphorylation, to binding of 14-3-3 proteins and nuclear export to the cytoplasm where it is degraded by the ubiquitin-proteosomal pathway (PubMed:11237865, PubMed:12228231). Phosphorylation at Ser-249 by CDK1 disrupts binding of 14-3-3 proteins and promotes nuclear accumulation (PubMed:18356527). Phosphorylation by NLK results in nuclear export (By similarity). Translocates to the nucleus upon oxidative stress-induced phosphorylation at Ser-212 by STK4/MST1 (PubMed:19221179, PubMed:21245099). SGK1-mediated phosphorylation also results in nuclear translocation (By similarity). Retained in the nucleus under stress stimuli including oxidative stress, nutrient deprivation or nitric oxide (By similarity). Retained in the nucleus on methylation (By similarity). PPIA/CYPA stimulates its nuclear accumulation (PubMed:31063815). Deacetylation by SIRT6, promotes its translocation into the cytoplasm (PubMed:25009184). .
show all
Tissue Expression:
Ubiquitous.
show all
Research Areas:
>>FoxO signaling pathway ;
>>AMPK signaling pathway ;
>>Longevity regulating pathway ;
>>Longevity regulating pathway - multiple species ;
>>Cellular senescence ;
>>Insulin signaling pathway ;
>>Thyroid hormone signaling pathway ;
>>Glucagon signaling pathway ;
>>Insulin resistance ;
>>AGE-RAGE signaling pathway in diabetic complications ;
>>Alcoholic liver disease ;
>>Shigellosis ;
>>Human papillomavirus infection ;
>>Pathways in cancer ;
>>Transcriptional misregulation in cancer ;
>>Prostate cancer